Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 159, Issue 5 I, 1999, Pages 1556-1561

  Nelson, Harold S ^a   Berkowitz, Robert B ^b   Tinkelman, David A ^b   Emmett, Amanda H ^b   Rickard, Kathleen A ^b   Yancey, Steven W ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL XINAFOATE;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0032914897     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.159.5.9807128     Document Type: Article

References (31)

1. Taylor, D. R., M. R. Sears, and D. W. Cockcroft. 1996. The beta-agonist controversy. Med. Clin. North Am. 80:719-748.
2. Nelson, H. S. 1997. Beta-adrencrgic agonists. In P. J. Barnes, M. M. Grunstein, A. R. Leff, and A. J. Woolcock, editors. Asthma. Lippincott Raven, Philadelphia. 1507-152.
3. 2-agonist therapy: vox damantis in deserto vel lux in tenebris? J. Allergy Clin. Immunol. 95: 641-651.
4. Ziment, I. 1993. Beta-adrencrgic agonist toxicity: less of a problem, more of a perception. Chest 103:1591-1597.
5. 2-adrenoceptor-agonisls - potential problems: development of tachyphylaxis. Monaldi Arch. Chest Dis. 48:254-261.
6. Nelson, H. S., L. B. Branch, and D. Raine. 1977. Beta-adrenergic subsensitivity induced by chronic administration of terbutalinc. Int. Arch. Allergy Appl. Immunol. 55:362-373.
7. Jenne, J. W., T. W. Chick, R. O. Strickland, and F. J. Wall. 1977. Subsensitivity of beta responses during therapy with long-acting beta-2 preparations, J. Allergy Clin. Immunol. 59:383-390.
8. Lipworth, B. J., A. D. Struthers, and D. E. McDevitt. 1989. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am. Rev. Respir. Dis. 140:586-592.
9. Maconochie, J. G., N. A. Minton, J. E. Chilton, and O. N. Keene. 1994. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Br. J. Clin. Pharmacol. 37:199-204.
10. Ullman, A., and N. Svedmyr. 1988. Salmeterol, a new long acting inhaled β2 adrenoreceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 43:674-678.
11. 2-agonist. Ann. Pharmacother. 27:1478-1487.
12. Boulet, L. P., M. Laviolette, S. Boucher, A. Knight, J. Herbert, and K. R. Chapman. 1997. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study. J. Allergy Clin. Immunol. 99:13-21.
13. Leblanc, P., A. Knight, H. Kreisman, C. M. Borkhoff, and P. R. Johnston. 1996. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma. Am. J. Respir. Crit. Care Med. 154:324-328.
14. Castle, W., R. Fuller, J. Hall, and J. Palmer. 1993. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. B.M.J. 306:1034-1037.
15. Britton, M. G., J. S. Earnshaw, and J. B. D. Palmer. 1992. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur. Respir. J. 5:1062-1067.
16. 2-agonist. Ann. Pharmacother. 27:1478-1487.
17. Grove, A., and B. J. Lipworth. 1995. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 346:201-206.
18. Hui, K. K. D., M. R. Conolly, and D. P. Tashkin. 1982. Reversal of human lymphocyte beta adrenoreceptor desensitization by glucocorticoids. Clin. Pharmacol. Ther. 32:566-571.
19. 2-adrenoreceptors: accelerated restoration of B-adrenoreceptor responsiveness by prednisolone and ketotifen. J. Clin. Invest. 76:1096-1101.
20. American Thoracic Society. 1987. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am. Rev. Respir. Dis. 136:225-244.
21. Crapo, R. O., A. H. Morris, and R. M. Gardner. 1981. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am. Rev. Respir. Dis. 123:659-664.
22. Neter, J., W. Wasserman, and M. Kutner. 1985. Applied Linear Statistical Models, 2nd ed. Irwin, Homewood, IL. 1059-1062.
23. Steel, R. G. D., and J. H. Torrie. 1980. Principles and Procedures of Statistics: A Biometrical Approach, 2nd ed. McGraw-Hill, New York. 504-506.
24. Wilding, P., M. Clark, J. T. Coon, S. Lewis, J. B. Rushton, J. Osborne, S. Cooper, and A. E. Tattersfield. 1997. Effect of long term treatment with salmeterol on asthma control: a double-blind, randomised cross-over study. B.M.J. 314:1441-1446.
25. Cheung, D., M. C. Timmers, A. H. Zwinderman, E. H. Bel, J. H. Dijkman, and P. J. Sterk. 1992. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N. Engl. J. Med. 327:1198-1203.
26. Ullman, A., J. Hedner, and N. Svedmyr. 1990. Inhaled salmeterol and salbutamol in asthmatic patients - an evaluation of asthma symptoms and the possible development of tachyphylaxis. Am. Rev. Respir. Dis. 142:571-575.
27. 2-receptor function and inflammatory cells. Allergy 47:477-483.
28. Booth, H., R. Bish, J. Walters, F. Whitehead, and E. H. Walters. 1996. Salmeterol tachyphylaxis in steroid-treated asthmatic subjects. Thorax 51:1100-1104.
29. National Asthma Education and Prevention Program. 1997. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD. NIH Publication No. 97-4051.
30. Woolcock, A., B. Lundback, N. Ringdal, and L. A. Jacques. 1996. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 153:1481-1488.
31. Greening, A. P., P. W. Ind, M. Northfield, and G. Shaw. 1994. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosleroid. Lancet 344:219-224.